case_images: PMC9951597_01
case_images: The 3rd day after intravenous immunoglobulin.
case_images: CCID-16-457-g0001.jpg
case_images: PMC9951597_01_CCID-16-457-g0001.jpg
case_images: f0001
case_images: The skin rashes developed sheet-like epidermal detachment and epidermal necrosis involving nearly 70% of the body surface area (Figure 1).
case_images: The 7th day after subcutaneous injection of adalimumab, AbbVie Inc. USA.
case_images: CCID-16-457-g0002.jpg
case_images: PMC9951597_01_CCID-16-457-g0002.jpg
case_images: f0002
case_images: The desquamation had occurred in part of the primary rashes (Figure 2).
case_images: The 35th day after subcutaneous injection of adalimumab, AbbVie Inc. USA.
case_images: CCID-16-457-g0003.jpg
case_images: PMC9951597_01_CCID-16-457-g0003.jpg
case_images: f0003
case_images: At the follow-up visit 45 days later, the majority of the skin lesions had disappeared (Figure 3).